Turn Biotechnologies

Turn Biotechnologies welcomes Hans Hofland, PhD, to the newly created role of SVP of Pre-Clinical Development where he will be leading the development of regenerative medicine therapies for the company’s dermatology, immunology, and ophthalmology programs in its fight to solve the problems associated with the diseases of aging. Dr. Hofland brings a wealth of experience to the company having worked with more than a dozen leading dermatology and Immunology companies throughout his career, and where he was involved with 13 INDs helping bring 10 different products to market. He most recently worked at Evommune, a clinical-stage biotechnology company he co-founded and served as senior vice president of research. Evommune – which develops novel therapies to treat immune-mediated chronic inflammatory diseases – raised more than $150 million and progressed its assets to the clinic.    Previously, Dr. Hofland headed Research and Nonclinical Development at Dermira, where he worked for more than seven years until the company’s acquisition by Eli Lilly. He earlier held the position of senior director of GlaxoSmithKline’s Center for Skin Biology, and prior to its acquisition by GlaxoSmithKline, held the same position at Stiefel Laboratories. He has additionally worked for many other leading biotechnology companies during his illustrious career.   Dr. Hofland received his doctorate in Pharmaceutical Sciences from the University of Leiden in the Netherlands. He holds 21 granted and pending patents and has written more than 25 scientific journal articles.   https://lnkd.in/gH2GSdvk #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research #innovation #turnbacktime #lnps #advancingderm #DermatologyInnovation Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

If you are in Boston attending the mRNA PD&M Summit this week please reach out to Travis McQuiston representing team Turn Biotechnologies to learn more about our cellular restoration therapies. #aging #epigenetics #mrna #innovation

Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at European Society for Dermatological Research (ESDR) in Lisbon this Week! Dr. Edward Hsia, PhD Turn Bio's Vice President of Dermatology, will share details about the company’s successful reversal of the effects of aging in fibroblasts by up to 10.4 years – more than double the previously reported improvement. He will also offer data from Turn Bio’s historic rejuvenation of human keratinocytes, which comprise 90% of the epidermis. It is the first time anyone has reported rejuvenation of keratinocytes. Hsia will present to dermatologists and other skin experts during a podium presentation at the European Society for Dermatological Research (ESDR) on Friday, Sept 6, from 4:30 p.m. to 5:30 p.m. (WEST). #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research #innovation #turnbacktime #lnps #ardd Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

Turn Biotechnologies to Present at ARDD 2024 in Copenhagen! Turn Biotechnologies will share its latest work in cell rejuvenation this week at ARDD, the world’s largest conference on aging research and longevity. Vittorio Sebastiano, company co-founder and head of research, will present information about Turn Bio’s successful reversal of the effects of aging in skin. Vittorio Sebastiano will speak on Thursday, Aug. 29, at the 11th annual Aging Research and Drug Discovery (ARDD) in Copenhagen. His presentation will be from 7:20 to 7:40 p.m. (CET). The company achieved the rejuvenation using its proprietary ERA™ technology to reprogram aged human fibroblasts and keratinocytes. #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research  #innovation #turnbacktime #lnps #ardd Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

More good news to share! If you’re in San Francisco today, be sure to catch our co-founder, Vittorio Sebastiano, speaking from 2-3pm at the INNOVIT - Italian Innovation and Culture Hub Conference for Italian Innovation as he shares Turn Bio’s latest research on our ERATM reprogramming mRNA platform. #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research #innovation #turnbacktime #lnps Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

We are proud to announce a partnership with Korean pharmaceutical company HanAll Biopharma, which has licensed Turn Bio’s technology to develop treatments for age-related eye and ear conditions. The agreement has a potential value of more than $300 million for the first of several products planned for development. This expands Turn Bio’s therapeutic development from dermatology and immunology to two more organs that are often afflicted by age-related diseases.  https://prn.to/4bY9WCK #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research #innovation #turnbacktime #lnps Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J. Naveen Bojjireddy PhD, EMBA.

Again, a very exciting week for Turn Biotechnologies, as Edward Hsia, PhD, VP of Dermatology will be presenting today at the @Society for Investigative Dermatology meeting in Dallas, TX from 4pm to 6pm in the Trinity Exhibit Hall. Please join us to hear about our latest advances in LNP-mediated mRNA for epigenetic reprogramming in skin during this prestigious conference. #longevity #regenerativemedicine #futureofmedicine #medical #biotechnology #healthcare #genetics #research #innovation #turnbacktime #lnps Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

Exciting and busy times for @Turn Bio this spring! Pleased to share that our co-founder and Head of Research, Vittorio Sebastiano will be the keynote speaker this afternoon at the AAPS’ #NBC2024 conference in San Francisco. If you’d like to hear the latest, please join us at 1pm in the Yosemite BC Hall at the Hilton Union Square. #longevity #regenerativemedicine  #futureofmedicine  #medical  #biotechnology  #healthcare  #genetics  #research  #innovation #turnbacktime #lnps Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.

Turn Biotechnologies is thrilled to share our attendance to speak at The Aesthetic Society meeting during the inaugural IMCAS regenerative medicine session at the invitation of Dr. Steven Cohen, MD, FACS and co-chair of IMCAS regenerative medicine. Edward Hsia, VP Dermatology, presented our latest data on epigenetic reprogramming in skin during a session comprised of leading plastic surgeons highlighting the potential for personalized regenerative medicine of the future. https://bit.ly/3y2ojXK #longevity #regenerativemedicine  #futureofmedicine  #medical  #biotechnology  #healthcare  #genetics  #research  #innovation #turnbacktime #lnps #advancingderm #DermatologyInnovation  Anja Krammer Sergio Ruiz Vittorio Sebastiano Marie-Louise Bots Ric Peterson Gus Rhodes Travis McQuiston Xin Chen Naveen Bojjireddy PhD, EMBA. Zeeshan Kamal Edward Hsia Mustafa Turkoz, PhD Mouhannad J.